I’ve heard people in the plastics industry say things like, “Even if plastics could cure cancer, people would hate it.” Okay, so let’s see what people think of plastic if it really does cure cancer.
|Image courtesy Nano Letters.|
According to an article, “Polymer Antibodies Efficiently Target and Eliminate Cancer Cells,” from the Moscow Institute of Physics and Technology (MIPT), a joint research team from Russia and the United Kingdom has demonstrated the possibility of developing new types of anti-neoplastic drugs based on nanoMIPs, or “plastic antibodies.”
These nanoMIPs are “synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells.” This finding could be a “paradigm shift” by bringing a high level of “specificity” to treating cancer, said the article. Typically, the big drawback to most cancer treatments is that they are not very good at targeting the cancer cells specifically. The result is that most treatments kill off everything—the good and the bad—often making the treatment as harmful as the disease itself.
Advances in cancer research have led to a better understanding of the molecular mechanisms and the primary agents responsible for tumor development. “New findings have enabled novel anti-neoplastic drugs that can distinguish between healthy and cancerous cells by acting on specific molecular targets,” said the article.
The research was carried out by an international team from the University of Leicester, University College London, the Institute of Cytology of the Russian Academy of Sciences and the Moscow Institute of Physics and Technology. The results of the study were published in Nano Letters.
New class of anti-neoplastic medicines
Cancer cells undergo rapid division and require a constant supply of “food” or “growth factors” to stimulate cell growth and proliferation, explained the article. Growth factors come from outside the cell and “can be identified by corresponding receptor proteins on the cell surface.” Treatments over the past two decades act on these “growth factors” to “suppress binding” to the cells and thus directly affect their enzyme activity.
The international research group “has shown that it is possible to develop a new class of anti-neoplastic medicines based on a kind of particle called nanosized molecularly imprinted polymers (nanoMIPs). NanoMIPs are a synthetic polymer alternative to antibodies with a 3D structure that enables them to bind only to a certain fragment of a target protein,” which “ensures their high specificity.”
Unlike antibodies, noted the article, these nanoMIPs can also carry additional anti-cancer agents. “In their research, the authors proved for the first time that it is possible to synthesize nanoMIPs capable of selectively binding to the amino acid sequences of their target proteins. The study also demonstrated the potential for nanoMIP application in targeted drug delivery.”
NanoMIPs are synthesized in the presence of a target protein, which leaves a mark on the nanoparticle, called “imprinting,” that “can be compared to mold casting” because the end product takes on the shape of the original template. This process gives nanoMIPs the ability to selectively recognize the “target molecule and bind to it.”